ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ BƯỚC MỘT BỆNH NHÂN UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ GIAI ĐOẠN IV CÓ ĐỘT BIẾN EGFR BẰNG AFATINIB TẠI BỆNH VIỆN UNG BƯỚU NGHỆ AN

Abstract

Objectives: Evaluate the effectiveness of first-line Affatinib treatment in stage IV EGFR-mutation non-small cell lung cancer patients and side effects. Subjects and methods: This is a retrospective, descriptive study at evaluating the results of first-line Afatinib treatment in stage IV EGFR-mutation non-small cell lung cancer patients at Nghe An Oncology hospital. In total, 54 patients were enrolled in the study from January 2020 to May 2024. Results: The average age was 69±10.02 months; the percentage of male was 64.8%, the figure for female was 35.6%. The majority of patients had performance status 0-1, accounting for 83.3%. The proportion of common EGFR mutations and uncommon EGFR mutation were 74% (Del19, L858R) and 26%, respectively. Most patients were started with doses of 30mg (50%) and 40mg (31.5%). The optimal dose was mainly 30 mg, accounting for 70.4%.The Disease Response rate was 77.8%; Disease Control Rate (DCR) was 94.6%. There was no difference in disease response rate with patient characteristics, such as sex, PS, smoking history, histological types, EGFR mutation types.The median progression-free survival (PFS) was 18±2.33 months (95% Confidence interval (CI), 14.29-23,45 months).The common side effects of afatinib included diarrhea (37%), skin rash (22.8%), paronychia (27.8%), stomatitis (27.8%), mainly in grade 1 and grade 2. The rates of skin rash and grade 3-4 paronychia were statistically significantly lower in the <40 mg treatment group compared with the 40 mg dose (p < 0.05).